VEGFA and laryngotracheoesophageal cleft: The VEGF pathway may induce the progression of LC tumors by activating malignant angiogenic, metastatistic, and proliferative programs of cancer cells, and it is the primary pharmacological target of antiangiogenic anticancer drugs [144–146].